MYGN
Ticker
Myriad Genetics Inc
Company
Diagnostics
Industry
Healthcare
Sector
Financial Ratio Analysis
+
2009
+
2010
+
2011
+
2012
+
2013
+
2014
+
2015
+
2016
+
2017
+
2018
+
2019
+
2020
+
2021
+
2022
+
2023
+
2024
+
2025
TTM
Revenue Growth YoY
β€”7.6%17.5%23.1%35.2%-1.7%3.0%0.8%1.1%4.6%2.2%-31.5%24.0%-1.8%11.0%11.2%β€”0.2%
Revenue Growth QoQ
β€”7.6%17.5%23.1%35.2%-1.7%3.0%0.8%1.1%4.6%2.2%-31.5%24.0%-1.8%11.0%11.2%β€”β€”
Gross Margin
87.3%88.0%87.8%86.9%87.2%82.0%79.7%78.1%77.1%75.9%75.6%68.0%71.4%70.2%68.6%69.9%β€”70.4%
EBITDA Margin
41.9%40.3%40.3%37.9%40.6%26.5%25.0%18.3%22.0%13.0%5.4%-39.2%-18.5%-13.0%-26.0%-7.4%β€”-44.2%
Operating Margin
38.2%38.5%38.5%36.2%39.3%23.6%21.5%13.6%15.1%4.9%-3.6%-52.0%-27.6%-20.7%-34.2%-14.7%β€”-51.0%
Profit Margin
32.7%35.3%24.2%22.7%25.5%15.2%14.4%8.4%16.4%3.2%-3.2%-40.2%-3.9%-16.5%-35.0%-15.2%β€”-48.5%
FCF / EBITDA
92.9%99.0%65.9%70.0%75.6%46.0%82.5%76.9%76.7%93.1%97.7%18.4%-0.5%172.5%94.2%61.6%β€”8.1%